50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
'A Gold Storm Is Coming' (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
'A Gold Storm Is Coming' (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
'A Gold Storm Is Coming' (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
'A Gold Storm Is Coming' (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
'A Gold Storm Is Coming' (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
'A Gold Storm Is Coming' (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Kim Kardashian culls Dolce&Gabbana archives for Milan show
NASDAQ:OSUR

OraSure Technologies - OSUR Stock Forecast, Price & News

$3.66
+0.07 (+1.95%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.45
$3.68
50-Day Range
$2.90
$4.61
52-Week Range
$2.62
$11.89
Volume
802,842 shs
Average Volume
730,570 shs
Market Capitalization
$265.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

OraSure Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
227.9% Upside
$12.00 Price Target
Short Interest
Healthy
4.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.09
Upright™ Environmental Score
News Sentiment
1.22mentions of OraSure Technologies in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$263,538 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.67) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.84 out of 5 stars

Medical Sector

56th out of 1,080 stocks

Surgical & Medical Instruments Industry

6th out of 104 stocks

OSUR stock logo

About OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

Receive OSUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

OSUR Stock News Headlines

OraSure Technologies gets new CEO
OraSure Technologies Misses Q1 EPS by 19c
See More Headlines
Receive OSUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OraSure Technologies and its competitors with MarketBeat's FREE daily newsletter.

OSUR Company Calendar

Last Earnings
8/09/2022
Today
9/24/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:OSUR
CUSIP
68554V10
Employees
785
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+227.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,000,000.00
Pretax Margin
-21.79%

Debt

Sales & Book Value

Annual Sales
$233.67 million
Book Value
$5.28 per share

Miscellaneous

Free Float
71,021,000
Market Cap
$265.79 million
Optionable
Optionable
Beta
-0.03

Key Executives

  • Mr. Scott Gleason (Age 43)
    Sr. VP of Investor Relations & Corp. Communications
    Comp: $362.92k
  • Ms. Kathleen Gallagher Weber (Age 54)
    Pres of Molecular Solutions
    Comp: $1.12M
  • Ms. Carrie Eglinton Manner (Age 47)
    Pres, CEO & Director
  • Mr. Kenneth J. McGrath
    Chief Financial Officer
  • Ms. Michele Marie Miller (Age 48)
    Sr. VP, Chief Accounting Officer, Controller & Assistant Sec.
  • Mr. David A. Rappaport C.F.A.
    CFA, Sr. VP Corp. Devel., Strategy & Integration
  • Amy Steigerwalt
    VP of HR
  • Ms. Lisa Nibauer (Age 53)
    Pres of Diagnostics













OSUR Stock - Frequently Asked Questions

Should I buy or sell OraSure Technologies stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OSUR shares.
View OSUR analyst ratings
or view top-rated stocks.

What is OraSure Technologies' stock price forecast for 2022?

2 analysts have issued 1 year price objectives for OraSure Technologies' shares. Their OSUR share price forecasts range from $10.00 to $14.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 227.9% from the stock's current price.
View analysts price targets for OSUR
or view top-rated stocks among Wall Street analysts.

How have OSUR shares performed in 2022?

OraSure Technologies' stock was trading at $8.69 at the start of the year. Since then, OSUR shares have decreased by 57.9% and is now trading at $3.66.
View the best growth stocks for 2022 here
.

When is OraSure Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our OSUR earnings forecast
.

How were OraSure Technologies' earnings last quarter?

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.12. The medical instruments supplier earned $80.23 million during the quarter, compared to analyst estimates of $69.91 million. OraSure Technologies had a negative net margin of 24.18% and a negative trailing twelve-month return on equity of 12.92%. OraSure Technologies's quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) earnings per share.

What guidance has OraSure Technologies issued on next quarter's earnings?

OraSure Technologies issued an update on its third quarter 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $90.00 million-$95.00 million, compared to the consensus revenue estimate of $76.15 million.

What is Stephen Tang's approval rating as OraSure Technologies' CEO?

2 employees have rated OraSure Technologies Chief Executive Officer Stephen Tang on Glassdoor.com. Stephen Tang has an approval rating of 100% among the company's employees. This puts Stephen Tang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OraSure Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), Energy Transfer (ET), XOMA (XOMA), Overstock.com (OSTK), Ford Motor (F), Pfizer (PFE), Abbott Laboratories (ABT), Advanced Micro Devices (AMD) and Activision Blizzard (ATVI).

What is OraSure Technologies' stock symbol?

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

Who are OraSure Technologies' major shareholders?

OraSure Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (4.74%), Renaissance Technologies LLC (3.32%), Kennedy Capital Management Inc. (1.55%), Primecap Management Co. CA (1.26%), Wells Fargo & Company MN (1.20%) and Northern Trust Corp (1.05%). Insiders that own company stock include Michael Celano, Nancy J Gagliano and Ronny B Lancaster.
View institutional ownership trends
.

How do I buy shares of OraSure Technologies?

Shares of OSUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OraSure Technologies' stock price today?

One share of OSUR stock can currently be purchased for approximately $3.66.

How much money does OraSure Technologies make?

OraSure Technologies (NASDAQ:OSUR) has a market capitalization of $265.79 million and generates $233.67 million in revenue each year. The medical instruments supplier earns $-23,000,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does OraSure Technologies have?

The company employs 785 workers across the globe.

How can I contact OraSure Technologies?

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The official website for the company is www.orasure.com. The medical instruments supplier can be reached via phone at (610) 882-1820, via email at investorinfo@orasure.com, or via fax at 610-882-1830.

This page (NASDAQ:OSUR) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.